A recent study published in Scientific Reports has demonstrated the antiviral effectiveness of cetylpyridinium chloride against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Cetylpyridinium chloride is an ammonium compound commonly present in mouthwash.
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19) pandemic, is an enveloped, positive-sense, single-stranded RNA virus belonging to the human betacoronavirus family. The virus and its more aggressive variants have caused unprecedented damage to the global healthcare system, with more than 590 million confirmed infections and over 6.4 million deaths.
The primary entry site of SARS-CoV-2 into the human body is the respiratory epithelium, which expresses high levels of the entry receptor angiotensin-converting enzyme 2 (ACE2). Evidence indicates that the virus can replicate in the oral cavity and release into saliva. The literature has also established an association between salivary content of SARS-CoV-2 and COVID-19 aggravation.
Considering the significance of oral hygiene in the context of SARS-CoV-2 infection, scientists in the current study have investigated the antiviral effect as well as the mode of action of cetylpyridinium chloride against SARS-CoV-2 infection.
Cetylpyridinium chloride is an antimicrobial compound widely used in mouthwash to prevent bacterial, fungal, or viral infections in the oral cavity. The compound is known to exert antimicrobial effects by disrupting lipid membrane via physicochemical interactions. A few studies have indicated that cetylpyridinium chloride is effective against wild-type SARS-CoV-2 at low concentrations (10–50 µg/ml).
Impact of cetylpyridinium chloride on SARS-CoV-2 infectivity
The study examined the antiviral effect of cetylpyridinium chloride on a range of SARS-CoV-2 strains, including wild-type SARS-CoV-2 and alpha, beta, and gamma variants. The plaque assay was conducted to examine viral infectivity in the presence and absence of the compound.
The findings revealed that cetylpyridinium chloride at low concentrations (5 – 40 µg/ml) significantly suppresses the infectivity of all tested SARS-CoV-2 strains in a dose-dependent manner. The tested concentrations were lower than that used in commercially available mouthwash (50 µg/ml).
Impact of cetylpyridinium chloride on viral entry
The findings revealed that cetylpyridinium chloride significantly reduces the expression and copy number of viral RNA in a dose-dependent manner. These findings indicate that cetylpyridinium chloride reduces the amount of infectious virus before host cell entry.
Antiviral activity of cetylpyridinium chloride in saliva
Human saliva is highly viscous and contains many proteins that may interfere with the antiviral efficacy of cetylpyridinium chloride. Saliva samples collected from healthy donors were mixed with the virus and cetylpyridinium chloride to determine the antiviral efficacy of the compound in saliva.
The findings revealed that cetylpyridinium chloride significantly suppresses viral infectivity even in saliva in a dose-dependent manner.
Antiviral mode of action of cetylpyridinium chloride
Cetylpyridinium chloride-treated SARS-CoV-2 was subjected to sucrose density analysis and transmission electron microscopy to determine the impact of cetylpyridinium chloride on viral morphology.
The findings revealed that cetylpyridinium chloride does not impact the overall structure of the virus. The spherical particle structure of SARS-CoV-2 remained unchanged after cetylpyridinium chloride treatment.
Study significance
The study highlights the potency of cetylpyridinium chloride in inhibiting SARS-CoV-2 and its variants even at low concentrations. The antiviral activity of the compound remains unchanged in human saliva.
The study has tested the antiviral efficacy of a commercial mouthwash that contains a similar concentration of cetylpyridinium chloride as used in the study. The mouthwash exhibits similar or even better antiviral efficacy than pure cetylpyridinium chloride solution. This indicates that the other ingredients present in the mouthwash do not interfere with the anti-SARS-CoV-2 activity of cetylpyridinium chloride.
Regarding mode of action, the study suggests that cetylpyridinium chloride exerts anti-SARS-CoV-2 activity most probably by denaturing viral proteins and not by disrupting lipid membrane.
Overall, the study indicates that cetylpyridinium chloride-containing products can be used as a preventive measure to reduce the transmission rate and progression of SARS-CoV-2 infection.
An ongoing clinical study is examining the effect of cetylpyridinium chloride on SARS-CoV-2 viral load in the saliva of COVID-19 patients.
News
Younger Generations Are Aging Faster – and It May Be Fueling a Surge in Cancer
Younger generations may be aging biologically faster than those before them, and that shift could help explain rising rates of cancer at younger ages. For decades, cancer was viewed largely as a disease of [...]
Using Cannabis Could Raise Your Stroke Risk by 37%, Massive Study Reveals
Large-scale evidence suggests cannabis, cocaine, and amphetamines may directly raise stroke risk, including in younger adults. As recreational drug use becomes increasingly common, researchers are uncovering evidence that its health consequences may extend far beyond [...]
Could Vitamin C Be the Secret to Keeping Your Brain Younger?
Lower vitamin C levels were linked to reduced brain volume and weaker neural connectivity in older adults, suggesting a potential connection between nutrition and brain health. Could a common vitamin help preserve the brain [...]
This Deadly Disease Was Wiping Out Humans 5,500 Years Ago
A new study suggests plague was already a deadly threat 5,500 years ago, striking small hunter-gatherer communities long before cities and agriculture emerged. For centuries, plague has been remembered as the disease that devastated [...]
China closing in but US leads in biotech quality, commercial reach, survey finds
SAN DIEGO, June 22 (Reuters) - China, which now conducts more clinical drug trials, opens new tab than the U.S., still lags in the quality and commercial reach of its biomedical science, according to a recent survey, opens new [...]
New method generates renewable supply of progenitor immune cells
In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages. These immune cells help [...]
Scientists Just Discovered a Cellular Survival System That Was Never Supposed To Exist
A surprising backup pathway allows cells to make a crucial amino acid when their primary machinery fails. For decades, biologists believed cells had only one way to access a molecule they cannot live without. New [...]
Artificial cells gain porous membranes, enabling lab reactions and drug release
Artificial cells created in the laboratory offer a wide range of potential applications. Until now, however, their membranes—unlike those of real cells—have been virtually impermeable. Researchers at the Max Planck Institute for Polymer Research, [...]
Popular Weight-Loss Drugs Like Ozempic Linked to Lower Breast Cancer Risk
Ozempic and similar weight-loss drugs were linked to a striking 30% reduction in breast cancer risk in a study of more than 110,000 women. Popular weight-loss and diabetes medications such as Ozempic, Wegovy, Mounjaro, [...]
Stanford Scientists Discover Explosive New Type of Immune Cell
Scientists studying the remarkable regenerative abilities of planarian flatworms have uncovered a previously unknown type of immune cell with an unusually destructive defense strategy. What if an immune cell could wipe out nearby threats [...]
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma. Vida Ventures led the raise, with the venture [...]
Joint initiative of 5 EU countries calls for ‘unified approach’ to pharma framework amid US drug pricing pressure
With drug pricing pressure building from the U.S., a healthcare-focused consortium of five European countries is calling for a “unified approach” to strengthen Europe’s pharmaceutical framework and access to innovative medicines. Belgium, the Netherlands, [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
NanoMedical Brain/Cloud Interface – Explorations and Implications. A new book from Frank Boehm
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
New book from Nanoappsmedical Inc. – Global Health Care Equivalency
A new book by Frank Boehm, NanoappsMedical Inc. Founder. This groundbreaking volume explores the vision of a Global Health Care Equivalency (GHCE) system powered by artificial intelligence and quantum computing technologies, operating on secure [...]
